PMID- 16190934
OWN - NLM
STAT- MEDLINE
DCOM- 20051031
LR  - 20181201
IS  - 0013-9580 (Print)
IS  - 0013-9580 (Linking)
VI  - 46
IP  - 10
DP  - 2005 Oct
TI  - Status epilepticus and tiagabine therapy revisited.
PG  - 1625-32
AB  - PURPOSE: To determine whether antiepileptic treatment with tiagabine (TGB) is 
      associated with an increased frequency of nonconvulsive status epilepticus (NCSE) 
      in patients with refractory epilepsy. METHODS: We reviewed retrospectively the 
      medical and EEG records of all inpatients with refractory localization-related 
      epilepsy at the National Society for Epilepsy treated with TGB between January 
      1997 and December 2000. Clinical and electroencephalographic (EEG) data before, 
      during, and after TGB therapy were evaluated in those patients who experienced a 
      deterioration in seizure control suggestive of NCSE. Frequency of NCSE was 
      determined in a comparable, non-TGB-treated patient population. RESULTS: Seven 
      (7.8%) of 90 TGB-treated patients were identified who experienced episodes of 
      electroclinically confirmed NCSE. Serial EEGs showed deterioration during TGB 
      treatment, with resolution of abnormality on discontinuation of TGB in all seven 
      patients. During the same observation period, 32 (2.7%) of 1,165 non-TGB-treated 
      patients developed electroclinically defined NCSE. CONCLUSIONS: Treatment with 
      TGB is associated with an increased frequency of NCSE in patients with refractory 
      localization-related epilepsy.
FAU - Koepp, Matthias J
AU  - Koepp MJ
AD  - Department of Clinical and Experimental Epilepsy, Institute of Neurology, UCL, 
      London, United Kingdom. mkoepp@ion.ucl.ac.uk
FAU - Edwards, Mark
AU  - Edwards M
FAU - Collins, Jayne
AU  - Collins J
FAU - Farrel, Fiona
AU  - Farrel F
FAU - Smith, Shelagh
AU  - Smith S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - 0 (Nipecotic Acids)
RN  - Z80I64HMNP (Tiagabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/*adverse effects/therapeutic use
MH  - Child
MH  - Electroencephalography/statistics & numerical data
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nipecotic Acids/*adverse effects/therapeutic use
MH  - Risk Factors
MH  - Status Epilepticus/*chemically induced/diagnosis/epidemiology
MH  - Tiagabine
MH  - United Kingdom/epidemiology
EDAT- 2005/09/30 09:00
MHDA- 2005/11/01 09:00
CRDT- 2005/09/30 09:00
PHST- 2005/09/30 09:00 [pubmed]
PHST- 2005/11/01 09:00 [medline]
PHST- 2005/09/30 09:00 [entrez]
AID - EPI263 [pii]
AID - 10.1111/j.1528-1167.2005.00263.x [doi]
PST - ppublish
SO  - Epilepsia. 2005 Oct;46(10):1625-32. doi: 10.1111/j.1528-1167.2005.00263.x.